Hypervision Surgical

The core of its offering is the HYPERSNAP® Surgical System, which combines hyperspectral imaging (HSI) and artificial intelligence to provide real-time, computer-assisted tissue analysis during surgery. This technology makes invisible tissue characteristics visible to the surgeon without the need for contact or contrast agents. The system is capable of wide-field tissue differentiation to identify tumors, normal tissue, and critical structures like nerves and blood vessels, and can assess tissue perfusion. The goal is to improve surgical precision, speed, and patient safety by providing surgeons with objective, data-driven information for better decision-making.

The company's business model focuses on creating a hardware-agnostic software solution that can integrate into existing surgical workflows, including minimally invasive, robotic, and microscopic surgeries. Having secured U.S. FDA 510(k) clearance and UKCA marking for its system, Hypervision Surgical is targeting the healthcare market in Europe and the United States. It is conducting clinical evaluation studies in colorectal and neurosurgery. In June 2023, the company raised £6.5 million in an oversubscribed seed funding round led by HERAN Partners, Redalpine, LifeX Ventures, and ZEISS Ventures to accelerate development and regulatory clearance.